Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033633 | 0.94 | TRPA1 (0.57) | TRPA1SMN1; SMN2RXFP1MEN1KMT2A | |
| SCHEMBL6704883 | 0.82 | TRPA1 (0.56) | TRPA1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7033357 | 0.80 | SMN1; SMN2 (0.54) | TRPA1MAPTSMN1; SMN2THRBKMT2A | |
| SCHEMBL6245168 | 0.77 | TRPA1 (0.62) | TRPA1MAPTSMN1; SMN2RXFP1ALDH1A1 | |
| SCHEMBL7021132 | 0.77 | TRPA1 (0.57) | TRPA1MAPTSMN1; SMN2RXFP1NPSR1 | |
| SCHEMBL7032058 | 0.76 | MMP13 (0.53) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL5957503 | 0.76 | TRPA1 (1.00) | TRPA1MAPTCNR2L3MBTL1TP53 | |
| SCHEMBL6731246 | 0.75 | TRPA1 (0.67) | TRPA1MAPTSMN1; SMN2RXFP1MEN1 | |
| SCHEMBL6257817 | 0.75 | TRPA1 (0.66) | TRPA1MAPTSMN1; SMN2THRBRXFP1 | |
| SCHEMBL6701930 | 0.75 | TRPA1 (0.54) | TRPA1MAPTSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | TRPA1 4283/4885MAPT 4548/4885SMN1; SMN2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.